Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer
Clinical trial NCT03923166 · UNKNOWN
Trial details
- NCT number
- NCT03923166
- Sponsor
- Chinese Academy of Medical Sciences
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-19
- Primary completion
- 2021-04-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.